Trofinetide: Daybue, first approved drug for Rett syndrome
A synthetic brain-protective compound taken as a daily oral liquid; the first-ever FDA-approved treatment for Rett syndrome, a rare genetic brain disorder that affects mostly girls.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Trofinetide (brand name Daybue) is a daily oral liquid medicine and the first treatment ever approved for Rett syndrome — a rare genetic brain disorder caused by mutations in the MECP2 gene that affects mostly girls. It is a synthetic, metabolically stabilized version of glycine-proline-glutamate (GPE), a three-amino-acid fragment that the brain naturally cleaves off the front of insulin-like growth factor-1 (IGF-1); the active drug carries a 2-methyl group on its proline (so the chemistry is Gly-2-methyl-Pro-Glu, not the bare GPE shown in the stored sequence), which lets it survive long enough in the bloodstream to be dosed by mouth (Cogo and colleagues, Drug Design, Development and Therapy, 2023; Neul and colleagues, Nature Medicine, 2023). It was developed by Neuren Pharmaceuticals out of academic work at the University of Auckland under the code name NNZ-2566, and licensed to Acadia Pharmaceuticals, which won FDA approval as Daybue in March 2023 (Keam, Drugs, 2023). It is a prescription drug — not a research peptide or nootropic — and although it produces meaningful symptom improvement, it does not correct the underlying MECP2 mutation and is not a cure.
History
The story begins in the 1990s in Peter Gluckman's lab at the University of Auckland, where work on IGF-1 showed that its naturally cleaved N-terminal tripeptide GPE ("glypromate") had neuroprotective activity in its own right, distinct from IGF-1 receptor signalling — but with a half-life too short for practical use. The chemistry program that followed substituted a 2-methyl group onto the proline to block proteolytic degradation, yielding the stabilized analogue NNZ-2566 (Cogo and colleagues, Drug Design, Development and Therapy, 2023). Neuren Pharmaceuticals took NNZ-2566 through early clinical work in traumatic brain injury, fragile X syndrome and Rett syndrome (Glaze and colleagues, Pediatric Neurology, 2017). TBI and fragile X did not yield approvals — a Phase 2 fragile X RCT produced mixed results (Berry-Kravis and colleagues, Journal of Child and Adolescent Psychopharmacology, 2020). The Rett program was licensed to Acadia Pharmaceuticals in 2018, ran a successful pivotal Phase 3 trial (LAVENDER), and was approved by the FDA in March 2023 — the first-ever disease-modifying treatment for Rett syndrome (Neul and colleagues, Nature Medicine, 2023; Keam, Drugs, 2023). Health Canada followed with approval in 2024.
What it does
In children and adults with Rett syndrome, trofinetide produces a measurable but partial improvement on the symptom scales clinicians use to track the condition — caregiver-rated behaviour and communication (the Rett Syndrome Behaviour Questionnaire, RSBQ) and clinician-rated overall change (CGI-I). In the 12-week Phase 3 LAVENDER trial, both endpoints separated statistically from placebo, which is what supported FDA approval (Neul and colleagues, Nature Medicine, 2023). It is an oral liquid taken twice a day and can be given through a gastrostomy tube — an important practical feature for the Rett population, where many patients have feeding difficulties (Neul and colleagues, Nature Medicine, 2023). It does not engage the IGF-1 receptor and is not an IGF-1 mimetic; mechanistically it appears to calm down neuroinflammation and support synaptic function (see Mechanism below).
Evidence
- Human: The pivotal evidence is the 12-week Phase 3 LAVENDER trial in girls and women with Rett syndrome, which showed statistically significant improvement over placebo on both co-primary endpoints (RSBQ and CGI-I) (Neul and colleagues, Nature Medicine, 2023). LAVENDER built on two earlier Phase 2 RCTs in adolescent/adult and pediatric Rett populations (Glaze and colleagues, Pediatric Neurology, 2017; Glaze and colleagues, Neurology, 2019). The open-label LILAC extension and the longer-term LILAC-2 study reported sustained benefit out to 32 months (Percy and colleagues, Med, 2024; Neul and colleagues, Med, 2024). The DAFFODIL Phase 2/3 study extended evidence into girls aged 2–4 years (Berry-Kravis and colleagues, Med, 2025). Multiple systematic reviews and meta-analyses have synthesized the trial evidence (Alessandrini and colleagues, BMC Pediatrics, 2024; BMC Medicine meta-analysis, 2024; Neurological Sciences meta-analysis, 2024). A separate Phase 2 RCT in fragile X syndrome reported mixed results (Berry-Kravis and colleagues, Journal of Child and Adolescent Psychopharmacology, 2020).
- Animal: Multiple studies in Mecp2-deficient mouse models of Rett syndrome have shown behavioural and neurological improvement and normalization of microglial and astrocyte morphology (reviewed in Cogo and colleagues, Drug Design, Development and Therapy, 2023). Beneficial effects have also been described in an APP/PS1 Alzheimer's mouse model — preclinical and exploratory only (Frontiers in Pharmacology, 2026).
- In vitro and pharmacokinetic: Phase 1 work in healthy adults characterized oral pharmacokinetics, mass balance, food effect and bioequivalence between formulations, and supported the weight-based dosing scheme used in LAVENDER (Darwish and colleagues, Clinical Drug Investigation, 2022; Darwish and colleagues, Clinical Drug Investigation, 2023). Exposure-response modelling and physiologically-based PK modelling underpin the label's dose adjustments in renal impairment (Darwish and colleagues, Advances in Therapy, 2024; European Journal of Drug Metabolism and Pharmacokinetics, 2024).
Myths and misconceptions
- "Trofinetide cures Rett syndrome." It is the first approved disease-modifying treatment, and LAVENDER showed statistically significant improvement on symptom measures — but it does not address the underlying MECP2 mutation and is not curative. The benefit is meaningful symptomatic improvement, not reversal of disease (Neul and colleagues, Nature Medicine, 2023).
- "Trofinetide is the same as IGF-1, or works through the IGF-1 receptor." It is a stabilized analogue of GPE, the tripeptide cleaved off IGF-1's N-terminus, and acts through pathways distinct from IGF-1 receptor signalling — modulation of microglial activation and synaptic function (Cogo and colleagues, Drug Design, Development and Therapy, 2023).
- "Diarrhea is rare or minor." Diarrhea is the most common adverse effect of trofinetide and was reported in the majority of treated patients in LAVENDER (Neul and colleagues, Nature Medicine, 2023). It is the leading cause of discontinuation and requires active management (Glaze and colleagues, Advances in Therapy, 2024).
- "Trofinetide is approved for general cognitive enhancement, neuroprotection or anti-aging." It is approved only for Rett syndrome in patients aged 2 years and older. There is no approved indication outside Rett syndrome and no published clinical evidence supporting nootropic or anti-aging use (Keam, Drugs, 2023).
- "Because it's a peptide-derived drug, it belongs in the same regulatory category as research peptides." Trofinetide is a fully approved, FDA-regulated prescription medicine with pharmaceutical-grade manufacturing and ongoing pharmacovigilance — a fundamentally different category from unapproved research peptides (Keam, Drugs, 2023).
Known effects
- Rett syndrome symptom improvement — FDA-approved (LAVENDER Phase 3) (Neul and colleagues, Nature Medicine, 2023).
- Sustained Rett syndrome symptom benefit to 32 months — open-label extension (LILAC, LILAC-2) (Percy and colleagues, Med, 2024; Neul and colleagues, Med, 2024).
- Fragile X syndrome symptoms — Phase 2 RCT, mixed results (Berry-Kravis and colleagues, Journal of Child and Adolescent Psychopharmacology, 2020).
- Anti-inflammatory effects (microglia normalization) — preclinical, in Mecp2-deficient models and exploratory neurodegeneration models (Cogo and colleagues, Drug Design, Development and Therapy, 2023; Frontiers in Pharmacology, 2026).
Safety signals
- Diarrhea — very common; reported in the majority of treated patients across the pivotal trial and post-marketing analysis. Leading cause of discontinuation; can cause dehydration; active monitoring is warranted (Neul and colleagues, Nature Medicine, 2023; Glaze and colleagues, Advances in Therapy, 2024).
- Vomiting — common; contributes to GI tolerability burden (Neul and colleagues, Nature Medicine, 2023).
- Weight loss — recognised concern, related to GI side effects (Neul and colleagues, Nature Medicine, 2023; Glaze and colleagues, Advances in Therapy, 2024).
- Dehydration risk — context-dependent; particularly relevant in patients with baseline feeding difficulties or G-tube use (Glaze and colleagues, Advances in Therapy, 2024).
- Trofinetide-induced enterocolitis syndrome — post-marketing case report; rare but clinically significant.
- Renal impairment — PK alteration — moderate renal impairment requires dose modification per label; PBPK modelling supports the label's dose-adjustment scheme (Darwish and colleagues, European Journal of Drug Metabolism and Pharmacokinetics, 2024).
- Pregnancy and lactation — limited human data; benefit-risk discussion per prescribing information (Keam, Drugs, 2023).
- Long-term safety beyond 32 months — not yet established; real-world post-marketing surveillance is ongoing (Percy and colleagues, Med, 2024; Neul and colleagues, Med, 2024).
Regulatory status
- US (FDA): Prescription-only. Approved as Daybue (oral solution; Acadia Pharmaceuticals) in March 2023 for Rett syndrome in adult and pediatric patients aged 2 years and older. Standard labeling, no REMS, with post-marketing pharmacovigilance ongoing (Keam, Drugs, 2023).
- Canada (Health Canada): Approved 2024 for Rett syndrome.
- EU (EMA): Review and approval status has evolved following US approval and should be confirmed against current EMA listings; the available literature predates the most recent EMA actions.
- WADA: Not on the WADA Prohibited List. The drug is not used or studied for performance enhancement.
Mechanism
Trofinetide is a synthetic, metabolically stabilized analogue of glycine-proline-glutamate (GPE), the N-terminal tripeptide of IGF-1 that is naturally cleaved in the brain. The chemistry is Gly-2-methyl-Pro-Glu — the IUPAC name reported in the LAVENDER paper is (2S)-2-{[(2S)-1-(2-aminoacetyl)-2-methylpyrrolidine-2-carbonyl]amino}pentanedioic acid — and the 2-methyl group on the proline is what gives the molecule a usable oral half-life relative to the parent GPE tripeptide (Neul and colleagues, Nature Medicine, 2023; Cogo and colleagues, Drug Design, Development and Therapy, 2023). The stored single-letter sequence "GPE" shown on this card does not capture this 2-methyl modification.
Despite its derivation from IGF-1, trofinetide does not engage the IGF-1 receptor; the mechanism is distinct from IGF-1 signalling (Cogo and colleagues, Drug Design, Development and Therapy, 2023). Two interlocking effects predominate in the published preclinical work. First, trofinetide modulates neuroinflammation: it normalizes microglial activation, reduces pro-inflammatory cytokine production and normalizes astrocyte and microglial morphology in Mecp2-deficient mouse models. Second, it supports synaptic maturation and function through modulation of the NMDA receptor and enhancement of neurotrophic signalling (Cogo and colleagues, Drug Design, Development and Therapy, 2023). In Rett syndrome, where MECP2 mutations disrupt neuronal development and lead to progressive neurological regression, this dual anti-inflammatory and neurotrophic-support profile is the working explanation for the clinical benefit seen in LAVENDER — but trofinetide does not correct the underlying MECP2 mutation, and the full mechanistic pathway is still being characterized in the research literature.
Open questions
- Long-term outcomes beyond 32 months. LILAC-2 demonstrated sustained benefit to 32 months (Neul and colleagues, Med, 2024); multi-year and lifelong outcome data — and effects on Rett syndrome mortality, seizure frequency and other hard endpoints — are still accumulating in post-marketing populations.
- Predictors of response. Rett syndrome has substantial phenotypic heterogeneity driven by MECP2 mutation type and location; identifying which patients are most likely to benefit, and which side-effect profiles to expect, is an active area of investigation.
- GI adverse-effect management. Management algorithms for diarrhea and weight loss have been published (Glaze and colleagues, Advances in Therapy, 2024), but standardized titration and supportive-care protocols are not yet uniformly established.
- Youngest pediatric population. DAFFODIL extended evidence into 2–4-year-olds (Berry-Kravis and colleagues, Med, 2025), but data in the very youngest patients remain comparatively limited.
- Other neurodevelopmental indications. The mechanistic rationale extends to fragile X syndrome (Phase 2 mixed results) and potentially other MECP2-related or synaptopathy disorders, as well as exploratory work in Alzheimer's models (Frontiers in Pharmacology, 2026), but no approved indication exists outside Rett syndrome.
Related peptides
- GPE (glypromate, Gly-Pro-Glu) — the unmodified parent tripeptide naturally cleaved from the N-terminus of IGF-1 in the brain. GPE is biologically active but rapidly degraded in plasma; the 2-methyl-Pro stabilization that produced trofinetide was the chemical solution to that instability (Cogo and colleagues, Drug Design, Development and Therapy, 2023).
- IGF-1 (insulin-like growth factor 1) — the parent protein from which the GPE tripeptide is naturally cleaved. Trofinetide is derived from IGF-1's N-terminus but does not engage the IGF-1 receptor and is mechanistically distinct from IGF-1 itself (Cogo and colleagues, Drug Design, Development and Therapy, 2023).
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does trofinetide actually produce its benefits through a different molecular switch than the IGF-1 receptor?
If true, researchers could redesign future drugs to hit the real target more precisely, potentially making them more effective or with fewer side effects for girls with Rett syndrome.
Could a drug approved specifically for Rett syndrome also help children with genetically different but similarly inflamed brain conditions?
If this holds, families affected by CDKL5 deficiency or FOXG1 syndrome, which currently have no approved medicines, could access a treatment that is already proven safe, shortcutting years of development time.
Does the modification that stops trofinetide from being broken down also make it harder for the brain's gatekeeping proteins to carry it inside?
If true, chemists could redesign the molecule to keep the stability improvement while restoring efficient brain entry, potentially allowing a smaller, easier-to-swallow dose for children with Rett syndrome.
Could wrapping trofinetide in a tiny particle or attaching it to a brain-targeting carrier make it work better with less medicine and no large liquid volume to swallow?
For girls with Rett syndrome, many of whom have difficulty swallowing, a nasal spray or small-volume injection form of trofinetide could be far easier to tolerate daily, potentially improving adherence and quality of life for both patients and caregivers.
Is the therapeutic effect of this tiny three-amino-acid drug driven by the specific angle it folds into, rather than which atoms it carries?
If the fold is the key, chemists could design small non-peptide molecules that mimic the same shape, potentially creating a pill-based successor to trofinetide that is cheaper to manufacture and easier for children to take.
Does trofinetide work by quieting a specific communication loop between hippocampal brain regions that becomes too loud in Rett syndrome?
If confirmed, doctors would have a concrete brain-activity signature to track when adjusting doses, and researchers would know exactly which circuit to target when building better drugs for Rett and related conditions.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.20736907422542572 | boltz-2 |
| ranking score | 0.45920243859291077 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | colabfold_local |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-22 |
▸citationbibtex
@peptide{pep10812,
sequence = {GPE},
target = {igf-1r},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}